How Much New Eli Lilly Product Launches Boosted the Bottom Line
Eli Lilly reported better-than-expected second-quarter earnings Thursday before the markets opened.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 257Why Bristol-Myers Squibb Solid Earnings Beat Failed to Impress
Bristol-Myers Squibb released better-than-expected second-quarter financial results before the markets opened Thursday.
Celgene Earnings Beat and Updated Guidance
Celgene released better-than-expected second-quarter earnings report Thursday before the markets opened.
Illumina Gets a Reset
Illumina reported mixed second-quarter financial results on Wednesday before the markets opened.
Biogen Faces Mixed Alzheimer’s Reception
It seems Biogen's closely watched Alzheimer's drug candidate, aducanumab, has fallen short of analyst and investor expectations.
Is This the End for XOMA?
XOMA Corp. (NASDAQ: XOMA) stumbled in trading Wednesday morning, perhaps fell off a cliff might be more accurate.
Is Thoratech Getting Enough Premium in its Buyout?
Both companies announced the approval for a definitive agreement in which St. Jude Medical will acquire Thoratec in a cash transaction valued at roughly $3.4 billion.
UnitedHealth Raises Over $10 Billion to Fund Catamaran Buyout
UnitedHealth Group has confirmed what investors were expecting with the sale of billions of dollars in debt.
How Exelixis Used Good News to Raise Over $100 Million in New Capital
It appears that Exelixis assumed now would be the best time to dilute following its most recent successful in clinical trial and get more bang for its buck.
Does Novavax Have the Answer for Ebola in New Trial?
Novavax is on the precipice of vaccinating Ebola, or at least according to its most recent clinical trial.
How Analysts Rated Lantheus After Quiet Period Ended
ThinkstockLantheus Holdings, Inc. (NASDAQ: LNTH), which is the parent company of Lantheus Medical Imaging, saw its quiet period come to an end on Monday. This expiration allows the analysts from its underwriters of the…
How Analysts View Glaukos After Its Quiet Period Ended
Wikimedia CommonsGlaukos Corporation (NYSE: GKOS) has been a strong performer since its initial public offering at the end of June. After selling 6 million shares at $18.00 per share, its current share price of…
Is UnitedHealth Now Fully Valued?
One analyst report does indicate that UnitedHealth may be fully valued. Other reports are not anywhere close to that conservative.
vTv Therapeutics Sets Expected Price Range for IPO
vTv Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
Horizon Pharma Sees Record Quarter Ahead
Horizon Pharma announced Monday morning that it expects its second-quarter financial results will be of record proportion.